Q1 Earnings Spotlight Cost Controls: Social media erupted with analysis of Recursion Pharmaceuticals' Q1 2026 earnings, noting a 56% revenue drop to $6.5 million due to lumpy milestones, yet applauding a 30% slash in cash operating expenses. This discipline extended the cash runway into early 2028, easing dilution fears in a tough biotech climate. Traders debated if this pivot from platform builder to clinical executor marks a turning point.
Clinical Progress Fuels Optimism: Buzz centered on REC-1245's clean safety profile with no dose-limiting toxicities in early trials, validating the AI-driven degrader design. REC-4881 drew praise for robust Phase 2 polyp reductions in familial adenomatous polyposis, with FDA engagement underway for a registrational pathway. The first dosing of REC-4539 further highlighted pipeline momentum.
Post-Earnings Dip Sparks Debate: Despite the revenue miss triggering a stock pullback, voices urged buying the dip, citing reaffirmed 2026 burn guidance under $390 million. Caution lingered over binary partnership inflows, but anticipation built for H2 regulatory updates. Overall, discussion reflects measured hope in Recursion's execution trajectory.
Note: This discussion summary was generated from an AI condensation of post data.
Recursion Pharmaceuticals Insider Trading Activity
Recursion Pharmaceuticals insiders have traded $RXRX stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $RXRX stock by insiders over the last 6 months:
- BLAKE BORGESON has made 0 purchases and 5 sales selling 860,000 shares for an estimated $3,525,800.
- CHRISTOPHER GIBSON has made 0 purchases and 10 sales selling 400,000 shares for an estimated $1,582,000.
- NAJAT KHAN (CEO and President) has made 0 purchases and 2 sales selling 152,701 shares for an estimated $643,251.
- BEN R TAYLOR (Chief Financial Officer) has made 0 purchases and 3 sales selling 42,765 shares for an estimated $157,703.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
Recursion Pharmaceuticals Revenue
Recursion Pharmaceuticals had revenues of $6.5M in Q1 2026. This is a decrease of -56.11% from the same period in the prior year.
You can track RXRX financials on Quiver Quantitative's RXRX stock page.
Recursion Pharmaceuticals Hedge Fund Activity
We have seen 201 institutional investors add shares of Recursion Pharmaceuticals stock to their portfolio, and 130 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MUBADALA INVESTMENT CO PJSC removed 12,985,927 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $53,112,441
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 12,712,693 shares (-75.7%) from their portfolio in Q4 2025, for an estimated $51,994,914
- NVIDIA CORP removed 7,706,363 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $31,519,024
- VANGUARD GROUP INC added 7,407,606 shares (+18.6%) to their portfolio in Q4 2025, for an estimated $30,297,108
- BLACKROCK, INC. added 7,127,014 shares (+22.5%) to their portfolio in Q4 2025, for an estimated $29,149,487
- STATE STREET CORP added 7,064,963 shares (+38.7%) to their portfolio in Q4 2025, for an estimated $28,895,698
- ARK INVESTMENT MANAGEMENT LLC added 3,771,357 shares (+11.2%) to their portfolio in Q4 2025, for an estimated $15,424,850
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Recursion Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $RXRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 12/17/2025
To track analyst ratings and price targets for Recursion Pharmaceuticals, check out Quiver Quantitative's $RXRX forecast page.
Recursion Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $RXRX recently. We have seen 4 analysts offer price targets for $RXRX in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Priyanka Grover from JP Morgan set a target price of $10.0 on 04/30/2026
- Michael Ryskin from B of A Securities set a target price of $6.0 on 02/26/2026
- Gil Blum from Needham set a target price of $8.0 on 02/26/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
